Erica Bell, PhD

Research Interest

Glioma, Cancer, Brain Cancer, Glioblastoma, DNA Damage, Lung Diseases

Erica Bell, PhD, focuses her research on understanding the mechanisms of radiation and chemotherapy resistance and sensitivity. In particular, Dr. Bell is interested in the identification of novel predictive and prognostic molecular biomarkers, specifically biomarkers that can be exploited therapeutically.

As a member of the world-renowned Translational Therapeutics program, her current field of research is focused on correlative analysis on clinical trial tissue and institutional cohorts including genomic, epigenomic, transcriptomic, metabolomic and proteomic profiling in order to detect novel tumor biomarkers that correlate with treatment efficacy and survival. She is currently performing whole genome profiling on tissue from multiple NRG Oncology trials. Her current disease-site focus for the biomarker research is adult and pediatric brain tumors as well as prostate cancer. Dr. Bell is also the co-inventor of a miRNA-based predictive model for the diagnosis and prognosis of prostate cancer, which has been submitted for patent approval. Additionally, she is focused on characterizing the effects of chromatin remodeling on DNA repair and chemoradiation resistance and sensitivity.

Dr. Bell’s work has appeared in well-respected publications, including the New England Journal of Medicine, JAMA Oncology, Journal of Clinical Oncology, Neuro-oncology, Clinical Cancer Research and Cancer Research. She also has presented her work to professional organizations around the globe, including NRG Oncology, American Society of Clinical Oncology, Society of Neuro-oncology, the World Federation of Neuro-oncology and the American Society for Radiation Oncology.